BAP1 Antibodies

Ubiquitin carboxyl-terminal hydrolase BAP1 (BAP1)

Deubiquitinating enzyme that plays an integral role in chromatin by mediating deubiquitination of histone H2A and HCFC1. Catalytic component of the PR-DUB complex, a complex that specifically mediates deubiquitination of histone H2A monoubiquitinated at'Lys-119' (H2AK119ub1).

Does not deubiquitinate monoubiquitinated histone H2B. Acts as a regulator of cell growth by mediating deubiquitination of HCFC1 N-terminal and C-terminal chains, with some specificity toward'Lys-48'- linked polyubiquitin chains in contrast to'Lys-63'-linked polyubiquitin chains.

Gene Information

Human
Gene Name:	BAP1
Uniprot:	Q92560
Entrez:	8314

Family

Belongs to:
peptidase C12 family

Alternative Names

BAP1; BRCA1 associated protein-1 (ubiquitin carboxy-terminal hydrolase); BRCA1-associated protein 1; Cerebral protein 6; cerebral protein-13; Cerebral Protein-6; DKFZp686N04275; EC 3.4.19.12; FLJ35406; FLJ37180; hucep-6; KIAA0272HUCEP-13; ubiquitin carboxyl-terminal hydrolase BAP1; ubiquitin carboxy-terminal hydrolase; UCHL2

Molecular Weight

Mass (kDA):
80.362 kDA

Genomic Context

Human
Location:	3p21.1
Sequence:	3; NC_000003.12 (52401004..52410030, complement)

Tissue Specificity

Highly expressed in testis, placenta and ovary. Expressed in breast.

Subcellular Localizations

Cytoplasm. Nucleus. Mainly nuclear. Binds to chromatin. Localizes to the cytoplasm when monoubiquitinated by the E2/E3 hybrid ubiquitin-protein ligase UBE2O (PubMed:24703950).

Diseases

• Neoplasms
• Malignant Neoplasms
• Melanoma
• Carcinoma
• Malignant Paraganglionic Neoplasm
• Uveal Melanoma
• Mammary Neoplasms
• Mesothelioma
• Uveal Neoplasms
• Neoplasm Metastasis
• Malignant Neoplasm Of Breast
• Malignant Neoplasm Of Lung
• Cell Transformation, Neoplastic

• Tissue Adhesions
• Renal Cell Carcinoma
• Cutaneous Melanoma
• Malignant Mesothelioma
• Pleural Neoplasms
• Cholera
• Skin Neoplasms

Interacting Proteins

• ASXL1
• BRCA1
• HCFC1
• ITPR3

Pathways

• Cell Cycle
• Cell Proliferation
• Localization
• Pathogenesis
• Cell Growth
• Cell Division
• Dna Repair
• Transport
• Cell Death
• Cell Adhesion
• Disease Resistance
• Gene Silencing
• Chemotaxis

• Angiogenesis
• Cell Migration
• Developmental Process
• Cell Differentiation
• Neutrophil Chemotaxis
• Humoral Immune Response
• Defense Response

PTMs

• Ubiquitination
• Phosphorylation
• Methylation
• Demethylation
• Reduction

• Cleavage
• Decarboxylation
• Acetylation
• Dephosphorylation
• Myristoylation

Research Areas

• Apoptosis
• Breast Cancer
• Cancer
• Cell Cycle and Replication
• Chromatin Research

• DNA Repair
• Tumor Suppressors

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/BAP1

Best Uses Of The BAP1 Marker In Breast Cancer

Breast cancer patients have the BAP1 marker on their skin. It is an enzyme that plays a role in the growth of cancer cell. There are many indicators of breast cancer. However, BAPE is the most prevalent. BAPE is also found in other tissues, like kidneys or the liver. In the laboratory BAPE can be classified into two kinds: malignant and premalignant breast cancer.

YY1

Applied Basic Research Program of Sichuan Province, Medical Research Project of Sichuan Province, Science and Technology Support Program of Nanchong, Chengdu Municipal Science and Technology Bureau, and Sichuan Provincial Department of Science and Tech. The BAP1 marker was designed to determine the level of expression for YY1. It is used to determine the likelihood of developing cancer. It will aid doctors in early detection.

31 liver and gastric cancer were analyzed for YY1 expression. The protein's expression was higher in ESCA tumors than in adjacent tissues and was statistically significant in predicting survival among ESCA patients. YY1 protein expression was also observed in the adjacent tissues of ESCA patients. Besides, BAP1 expression has a direct relationship with the underlying disease.

YY1 is a key marker of the transcriptome. Its expression in ESCA is extremely high and could play a role in ESCA progress. The transcriptome has many functions that YY1 plays. It has been demonstrated that YY1 plays a key role in the regulation of glutamine metabolism. Further, it has a important role in ESCA progression.

Galectin-3

There are many applications for the BAP1 gene in breast cancer. This gene is involved in homologous recombination and defective repair of DNA. If the BAP1 gene is not functioning in a breast cancer patient this biomarker might provide an alternative treatment option. These treatments can cause severe side effects, such as the development of breast cancers.

BAP1 may be a candidate for malignant pleural fluid (MM) however, the high amount of mutations means that it is unlikely to be a viable therapeutic target. Patients with BAP1 mutations are more likely to develop MM than patients with lower levels. This marker can aid in the early detection of MM, and may be useful clinically when used in conjunction other prognostic markers.

CYFRA21-1

The BAP1 marker is the best candidate to detect MPM. This molecule plays an essential role in the deficiency of DNA repair homologous or homologous recombination and other processes. It can be utilized for a myriad of reasons. Here are a few of its most beneficial uses. Below are a few of them.

Levels of CYFRA21-1 at BAPE

The present study compared the specificity and sensitivity of CYFRA21-1 levels in patients with early-stage MPM and BAPE. BAPE had lower CYFRA21-1 levels than MPM patients. SLPI also had an AUC higher than GAlectin-3 or SMRP. While SLPI was superior to SMRP and HA however, it was not as sensitive as SMRP or GAlectin-3.

The CYFRA21-1 fragment, which is a part of the protein cytokeratin19, is part of the intermediate filament protein (IFPs) that aid in maintain the epithelial cell's structure. Serum CYFRA 21-1 is elevated in a variety of epithelial malignancies, such as non-small cell lung cancer. Patients with pancreatic cancer had better outcomes and better prognosis if they had higher levels of CYFRA21-1.

Monoclonal antibody was used to confirm the presence of CK19 in the lung cancer specimen. All pure lung adenocarcinomas included CK19. The expression of CYFRA21-1 was strongly correlated with intracellular CK19 levels. This could be the result from the higher degradation rate of intracellular CK19 and the greater tendency to differentiate into squamous cell carcinoma.

SLPI

Boster Bio: The Best Uses For The Protein A (BAP1) is a targeted gene therapy that targets defects in DNA repair. BAP1 is thought to be essential for homologous recombination, and it may be able to treat patients suffering from a wide variety of MPM. BAP1 is also associated with various genetic disorders, like BAP1 mutations that affect the repair of DNA and cellular proliferative.

Immunohistochemistry

Numerous recent studies have demonstrated the utility of the BAP1 marker for the detection of breast cancer. BAP1 levels are elevated in the breast cancer samples from patients with kinetoplastin-receptor-positive (KIR) disease, and BAP1 loss is associated with a decreased level of the inflammatory response-related protein LFA-1. This marker can also be used to detect liver and gastrointestinal metastasis and encourage healing.

Cytology

BAP1 is a protein that is associated with BRCA1, and its expression correlates with the patient's prognosis in paraffin-embedded melanomas of the uveal region. However, it is unknown whether BAP1 is expressed in fine-needle aspiration biopsies. The present study examined the relationship between immunocytochemistry BAP1 nuclear staining and gene expression profiling in 113 patients with melanomas in the uveal area.

However this cytology marker will not be useful in desmoplastic mesothelioma because the cellularity of this tumor is not uniform, and it can be difficult to differentiate it from the true sarcomatoid component. In this case BAP-1 immunohistochemistry is of limited use. It can however be useful in identifying tumors lacking BAP1 expression.

Because MTAP is not released into the effusion, it could interfere with the diagnostic accuracy of the cytology specimen. For instance, patients with MPM are not often diagnosed with effusion cytology. Additionally, research suggests the use of IMP-3 and p53 for MPM over mesothelial cells that are reactive. Despite this, further research is required to confirm the efficacy of BAP1 as a reliable marker in MPM.

Determination of malignant and reactive pleural effusions

A new study has revealed that a boster bio BAP1 marker to detect reactive versus malignant pleura is highly specific and sensitive mesothelioma-related ancillary marker. In a series of 30 patients, BAP1 expression was detected in just 5 of 100 (5.1%) of benign effusions, however one patient could have had mesothelioma. Two patients had pleural effusions with mesothelial cell types that were not normal in a subsequent review.

In addition, the study showed that the Boster Bio BAP1 marker is highly specific for malignant pleural fibrisis. The authors found that the loss of BAP1 can improve diagnostic accuracy over routine IHC studies. However it is important to remember that BAP1 is absent in mesothelial proliferation that is not typical, which does not necessarily exclude malignancy. The study showed that only seven patients had malignancy and that three had reactive pleural effusion.

A BAP1 immunohistochemistry study of tissue samples from 25 patients revealed that the results were in line with the results of a tissue biopsy. Only one of the mesothelioma patients had positive BAP1 immunohistochemistry result. The other patients did not have test results for BAP1 antibodies. Table 1 and Figure 2 illustrate the results.